From: Monocyte-derived transcriptomes explain the ineffectiveness of abatacept in rheumatoid arthritis
 | Responders | Non-responders | OR (95% CI) | Pa |
---|---|---|---|---|
Total | 7 | 15 | Â | Â |
Age | 68.0 (60.6–73.5) | 66.0 (64.5–70.5) | ND | 0.97 |
Female (%) | 7 (100) | 12 (80) | 0.00 (0.00–5.3) | 0.52 |
BMI | 19.5 (18.9–23.0) | 24.3 (22.2–26.0) | ND | 0.09 |
Smoking history (%) | 0 (0) | 3 (23.4) | Inf (0.15–Inf) | 0.52 |
Duration of RA (years) | 11.1 (7.1–22.7) | 13.0 (5.6–19.7) | ND | 0.78 |
CRP (mg/dL) | 0.6 (0.4–1.3) | 0.7 (0.3–1.8) | ND | 0.67 |
ESR (mm/h) | 30.0 (24.0–39.5) | 35.0 (18.0–49.0) | ND | 0.80 |
RF positivity (%) | 6 (85.7) | 13 (86.7) | 1.08 (0.02–24.8) | 1.00 |
Anti-CCP positivity (%) | 7 (100) | 11 (73.3) | 0 (0–3.2) | 0.26 |
MTX usage (%) | 3 (42.9) | 9 (60.0) | 1.94 (0.23–18.5) | 0.65 |
MTX dosage†(mg/week) | 0.0 (0.0–6.0) | 6.0 (0.0–8.0) | ND | 0.46 |
PSL usage (%) | 2 (28.6) | 8 (53.3) | 2.7 (0.3–37.4) | 0.38 |
PSL dosage†(mg/day) | 0.0 (0.0–2.5) | 6.0 (0.0–8.0) | ND | 0.46 |
Previous b/tsDMARDs usage (%) | 3 (42.9) | 6 (40.0) | 0.89 (0.10–8.43) | 1.00 |
cDMARDs usage (%) | 4 (57.1) | 11 (73.3) | 1.99 (0.20–19.2) | 0.63 |
SE (%) | 11 (73.3) | 5 (71.4) | 1.1 (0.1–11.2) | 1.00 |
DAS28-ESR (0 months) | 4.4 (4.0–4.6) | 5.3 (3.5–5.6) | ND | 0.36 |
DAS28-ESR (3 months) | 2.8 (2.3–3.0) | 3.4 (2.9–4.2) | ND | 0.07 |
Cellular phenotype (× 103/μL) | ||||
 White blood cell | 5.43 (5.19–7.24) | 7.18 (5.15–10.6) | ND | 0.62 |
 Neutrophil | 3.75 (3.12–5.12) | 4.92 (3.29–8.86) | ND | 0.53 |
 Lymphocyte | 1.40 (1.10–1.70) | 1.20 (1.00–1.30) | ND | 0.32 |
 CD3 + cell | 1.02 (0.77–1.16) | 0.72 (0.49–0.88) | ND | 0.09 |
 CD19 + cell | 0.19 (0.10–0.20) | 0.11 (0.07–0.24) | ND | 0.78 |
 CD56 + cell | 0.23 (0.19–0.28) | 0.22 (0.16–0.32) | ND | 0.83 |
 Monocyte | 0.28 (0.23–0.30) | 0.43 (0.31–0.55) | ND | 0.02 |
 Eosinophil | 0.13 (0.04–0.21) | 0.10 (0.05–0.18) | ND | 0.86 |
 Basophil | 0.03 (0.02–0.06) | 0.07 (0.03–0.08) | ND | 0.62 |